How have CGIX shares performed in 2023?

Cancer Genetics' stock was trading at $0.1570 at the beginning of 2023. Since then, CGIX stock has increased by 13.1% and is now trading at $0.1775. View the best growth stocks for 2023 here .

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com . Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM) , OPKO Health (OPK) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Activision Blizzard (ATVI) , Ford Motor (F) , Gilead Sciences (GILD) , CymaBay Therapeutics (CBAY) , Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD) .

How do I buy shares of Cancer Genetics?

Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cancer Genetics Stock Price, News & Analysis (NASDAQ:CGIX)

$0.18

0.00 (0.00%)

(As of 11/29/2023 ET)

Today's Range: $0.18
▼
$0.18
50-Day Range: $0.14
▼
$4.61
52-Week Range: $2.11
▼
$17.50

Volume: 9,316 shs
Average Volume: 2.44 million shs
Market Capitalization: $725,087.50

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Social Media

About Cancer Genetics Stock (NASDAQ:CGIX)

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

CGIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CGIX Stock News Headlines

November 29, 2023 | americanbankingnews.com

Cancer Genetics (NASDAQ:CGIX) Now Covered by StockNews.com

November 21, 2023 | americanbankingnews.com

Cancer Genetics (NASDAQ:CGIX) Now Covered by Analysts at StockNews.com

See More Headlines

Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: N/A
Sub-Industry: N/A
Sector: Health Care and Social Assistance
Current Symbol: NASDAQ:CGIX
CUSIP: N/A
CIK: N/A
Web: www.cancergenetics.com
Phone: (201) 479-1357
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $6.33 million
Price / Sales: 0.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,085,000
Free Float: N/A
Market Cap: $725,087.50
Optionable: Not Optionable
Beta: 2.72

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Andrew D. C. LaFrence
President, Chief Executive & Financial Officer

CGIX Stock Analysis - Frequently Asked Questions

How have CGIX shares performed in 2023?: Cancer Genetics' stock was trading at $0.1570 at the beginning of 2023. Since then, CGIX stock has increased by 13.1% and is now trading at $0.1775.
View the best growth stocks for 2023 here.
What is Panna Sharma's approval rating as Cancer Genetics' CEO?: 28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Cancer Genetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Activision Blizzard (ATVI), Ford Motor (F), Gilead Sciences (GILD), CymaBay Therapeutics (CBAY), Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD).
How do I buy shares of Cancer Genetics?: Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CGIX) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial